13F Pro Quality Score

33.0/100

Rank #2,406 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

85.9/100

Profitability

7.1/100

Balance Sheet

13.4/100

Earnings Quality

37.0/100

Free Cash Flow

9.8/100

Institutional Flow

52.6/100

Revenue Scale

7.0/100

Dilution Risk

3.4/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Unusual Activity in OABI

Events flagged as statistical outliers against OABI's own multi-year baseline — not fixed dollar thresholds.

OABI Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for OmniAb, Inc. (OABI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OABI at 33.0/100 on a 32-signal composite quality model, placing it at rank #2,406 of 2,962 stocks — the bottom half of the AI-ranked universe. OABI scores in the top quartile across revenue growth (85.9). Areas of concern include revenue scale (7.0) and profitability (7.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), OmniAb, Inc. reports quarterly revenue of $13.4M, net income of $-5.9M, free cash flow of $2.6M. Top institutional holders of OABI by reported 13-F value include Whitefort Capital Management, BlackRock, NOMURA, based on the most recent SEC filings. OABI trades on the Nasdaq exchange and files with the SEC under CIK 1846253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OABI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OmniAb, Inc. directly from SEC EDGAR. OmniAb, Inc.'s 13F Pro composite quality score has ranged between 6 and 43 since 2023, currently 33.0 — a stable long-term trajectory across 60 quarterly and live scoring snapshots.

Fun facts about OmniAb, Inc.

Quirks, history, and lore behind OABI — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in California.
  • 2
    The Numbers
    A pre-profitability biotech with annual revenue in the tens of millions, funded largely by partnerships and licensing deals with larger pharmaceutical companies.
  • 3
    The History
    The company went public via a SPAC merger in late 2022, spinning out of Ligand Pharmaceuticals to stand on its own as a dedicated antibody-discovery platform.
  • 4
    The Secret
    Its core trick is engineering transgenic animals — including chickens — whose immune systems churn out fully human antibodies that drug companies can turn into therapeutics.
  • 5
    The Lore
    Using chickens as antibody factories sounds like a science-fair project, but the approach unlocks targets that mice and rats simply can't reach — giving partners a meaningful edge in drug discovery.
  • 6
    The Giveaway
    Its name literally means "all antibodies" — an Omni-vorous platform for generating Abodies from transgenic animals, spun out of Ligand and traded under a ticker that matches its name letter for letter.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$13.4M

Net Income

Q2 2026

$-5.9M

Free Cash Flow

Q2 2026

$2.6M

ROIC

Q2 2026

-10.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-29.3% YoY
$18.7MFY 2025
FY22 $59.1MFY23 $34.2MFY24 $26.4MFY25 $18.7M

Net Income

-4.4% YoY
$-64.8MFY 2025
FY22 $-22.3MFY23 $-50.6MFY24 $-62.0MFY25 $-64.8M

Operating Income

+7.4% YoY
$-69.0MFY 2025
FY22 $-26.6MFY23 $-69.4MFY24 $-74.5MFY25 $-69.0M

EPS (Diluted)

+6.6% YoY
$-0.57FY 2025
FY22 $-0.26FY23 $-0.51FY24 $-0.61FY25 $-0.57

Total Assets

-7.6% YoY
$300.9MFY 2025
FY22 $421.2MFY23 $375.2MFY24 $325.6MFY25 $300.9M

Op. Cash Flow

+8.1% YoY
$-36.5MFY 2025
FY22 $-3.6MFY23 $2.3MFY24 $-39.7MFY25 $-36.5M

Free Cash Flow

+10.9% YoY
$-37.0MFY 2025
FY22 $-20.8MFY23 $703.0KFY24 $-41.5MFY25 $-37.0M

Get alerted when OABI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OmniAb, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of OABI

Companies Similar to OABI

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BCYC

BICYCLE THERAPEUTICS PLC

26
AI score
Similar quality profile · 5 shared holders
JANX

Janux Therapeutics, Inc.

30
AI score
Similar quality profile · 4 shared holders
SIBN

SI-BONE, Inc.

43
AI score
Similar quality profile · 6 shared holders
NPCE

NeuroPace Inc

32
AI score
Similar quality profile · 3 shared holders
CHRS

Coherus Oncology, Inc.

5
AI score
Similar quality profile · 5 shared holders
KURA

Kura Oncology, Inc.

28
AI score
Similar quality profile · 3 shared holders
PGEN

PRECIGEN, INC.

30
AI score
Similar quality profile · 5 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put OABI on your watchlist

Track score changes the day OmniAb, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is OABI a good stock to buy?

13F Pro's AI-powered analysis of OmniAb, Inc. (OABI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OABI are available on the OABI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OABI is classified as a small company.

Which hedge funds own OABI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OABI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OmniAb, Inc.'s investment landscape.